Hematology Debate 2016 Invitation

Lively Passionate

Enlightening

Hematology Debate 2016 Invitation Program starts

Moderator

12:15 on Thursday 18 February 2016

Catherine Hood, UK

Hotel departures from

Scientific Committee

16:00 on Friday 19 February 2016

Peter Hillmen, UK María-Victoria Mateos, Spain Simon Rule, UK

Location Hilton Stadtpark, Vienna, Austria

An application has been made to the EACCME® for CME accreditation of this event

Lively Passionate

Dear Colleague It is our pleasure to invite you to participate in the Hematology Debate being held on Thursday 18 February – Friday 19 February 2016 in Vienna, Austria. This post-ASH Hematology Debate has been developed to offer a mix of educational plenary sessions and interactive workshops to provide scientific and clinical updates on topics relating to a range of hematological malignancies, with a specific focus on multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström’s macroglobulinemia. The format means you will have the opportunity to choose your workshop topics and tailor your own personalized program.

Enlightening

We hope you are able to join us in Vienna for what promises to be an informative and educational meeting.

Peter Hillmen

María-Victoria Mateos

Simon Rule

Scientific Committee

Scientific Committee

Scientific Committee

Faculty Jacqueline Barrientos, USA Christian Buske, Germany Florence Cymbalista, France Michel Delforge, Belgium Meletios A Dimopoulos, Greece Robin Foà, Italy Gianluca Gaidano, Italy Georg Hess, Germany Heinz Ludwig, Austria Mohamad Mohty, France

Philippe Moreau, France Carol Moreno, Spain Antonio Palumbo, Italy Pieter Sonneveld, The Netherlands Patrick Thornton, Ireland Steven Treon, USA Katja Weisel, Germany Agnieszka Wierzbowska, Poland Sonja Zweegman, The Netherlands

Educational objectives After attending this meeting, delegates should be able to: ¢  Discuss treatment options for patients with chronic lymphocytic leukemia, B-cell lymphoma, and multiple myeloma ¢  Identify strategies for the practical management of patients with specific hematological malignancies.

Program Thursday 18 February 2016 12:15–12:25 Welcoming remarks and introduction María-Victoria Mateos and Catherine Hood 12:30–14:00

Parallel workshop session



Topic 1: Diagnosis and response assessment in multiple myeloma

 Educational objective: List key diagnostic and response assessment criteria for multiple myeloma Workshop faculty: Michel Delforge, Meletios A Dimopoulos, Heinz Ludwig, María-Victoria Mateos, Mohamad Mohty, Philippe Moreau, Antonio Palumbo, Pieter Sonneveld, Katja Weisel, and Sonja Zweegman 14:00–14:15

Coffee

14:15–15:00  Plenary session – First-line treatment of multiple myeloma: updates from ASH 2015 Chair: María-Victoria Mateos

Educational objective: Identify first-line treatment options for young and older patients with multiple myeloma

¢ Treatment of young patients Philippe Moreau ¢ Treatment of elderly patients Antonio Palumbo Panel discussion 15:00–15:15

Coffee

15:15–16:45

Parallel workshop session

Topic 2: How I manage my myeloma patients  Educational objective: Discuss practical management approaches for patients with multiple myeloma Workshop faculty: Michel Delforge, Meletios A Dimopoulos, Heinz Ludwig, María-Victoria Mateos, Mohamad Mohty, Philippe Moreau, Antonio Palumbo, Pieter Sonneveld, Katja Weisel, and Sonja Zweegman 16:45–17:10

Coffee

17:10–18:10  Plenary session – Options for previously treated multiple myeloma: updates from ASH 2015 Chair: Pieter Sonneveld Educational objective: Summarize latest data with new agents in multiple myeloma ¢ Current treatment approaches for relapsed/refractory multiple myeloma Meletios A Dimopoulos ¢ The role of monoclonal antibodies in multiple myeloma María-Victoria Mateos Panel discussion 18:15–19:15 Meet the expert and networking session 20:00 Dinner

Friday 19 February 2016 08:30–08:45 Welcoming remarks Catherine Hood 08:45–09:45 Plenary session – A focus on first-line treatment options for chronic lymphocytic leukemia: an update from ASH 2015 Chair: Peter Hillmen Educational objective: Identify first-line treatment options for patients with chronic lymphocytic leukemia ¢ Current and emerging options for front-line treatment of chronic lymphocytic leukemia Jacqueline Barrientos Panel discussion 09:45–10:00

Coffee

10:00–11:30

Parallel workshop session

Topic 1: Managing relapsed/refractory chronic lymphocytic leukemia  Educational objective: Define management strategies for patients with relapsed/refractory chronic lymphocytic leukemia  Workshop faculty: Jacqueline Barrientos, Florence Cymbalista, Robin Foà, Gianluca Gaidano, Peter Hillmen, Carol Moreno, and Patrick Thornton Topic 2: Practical management of patients with mantle cell lymphoma Educational objective: Discuss the practical management of patients with mantle cell lymphoma  Workshop faculty: Georg Hess and Simon Rule

Topic 3: Practical management of patients with Waldenström’s macroglobulinemia Educational objective: Discuss the practical management of patients with Waldenström’s macroglobulinemia  Workshop faculty: Christian Buske and Steven Treon  Topic 4: Practical management of patients with acute myeloid leukemia Educational objective: Discuss the practical management of patients with acute myeloid leukemia  Workshop faculty: Agnieszka Wierzbowska and TBC 11:30–11:45 Coffee 11:45–12:45  Educational plenary session – Advances in the treatment of mantle cell lymphoma and Waldenström’s macroglobulinemia: updates from ASH 2015 Chair: Georg Hess Educational objective: Describe treatment approaches for patients with Waldenström’s macroglobulinemia and mantle cell lymphoma ¢ Update on Waldenström’s macroglobulinemia Steven Treon ¢ Update on mantle cell lymphoma Simon Rule

Panel discussion

12:45–13:45

Lunch

13:45–15:15  Parallel workshop session (topics repeated from previous workshop session) 15:15–15:30 Coffee 15:30–16:00  Plenary session – What are the implications of the ASH updates for our clinical practice? Chairs: Simon Rule and Peter Hillmen ¢ Summary and conclusions Simon Rule Panel discussion 16:00

Meeting close

Organized and supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA Janssen Pharmaceutica NV Turnhoutseweg 30 Beerse, Belgium

PHEM/HEM/1015/0001a

Janssen-Cilag Pharma GmbH Vorgartenstraße 206b A-1020 Wien, Austria

Copyright © 2015 Janssen Pharmaceutica NV